Amgen’s Repatha shown cost‑effective and to lower long‑term CV events when used earlier
- Independent VESALIUS‑CV economic analysis found Repatha cost‑effective at ~36% below the ACC/AHA benchmark.
- VESALIUS‑CV: Repatha cut 3‑P MACE by 25%, 4‑P MACE by 19%, and heart attack by 36%; median LDL was 45 mg/dL versus 109 mg/dL on placebo.
- In patients with CKD and no prior events, Repatha lowered 3‑P MACE by 39%, 4‑P MACE by 23% and all‑cause death by 29% versus placebo.
- FOURIER external‑control analysis over >8 years associated Repatha with a 29% lower rate of 3‑P MACE and 25% lower CV death.
Cost‑effectiveness evidence
An independent, patient‑level economic analysis using VESALIUS‑CV data led by Duke with the TIMI Study Group found Repatha to be cost‑effective for high‑risk patients without prior heart attack or stroke, at approximately 36% below the ACC/AHA benchmark. A separate analysis showed adding Repatha to standard therapy was also highly cost‑effective in adults with established ASCVD.
VESALIUS‑CV trial results
VESALIUS‑CV enrolled >12,000 high‑risk patients without prior myocardial infarction or stroke and treated them with maximally tolerated statin±ezetimibe. Over a median 4.6 years, Repatha reduced 3‑P MACE (CHD death, MI, ischemic stroke) by 25%, 4‑P MACE by 19%, and MI by 36%. A lipid sub‑study showed median on‑treatment LDL‑C of 45 mg/dL versus 109 mg/dL for placebo.
CKD subgroup
Pre‑specified analyses found patients with chronic kidney disease had ~90% higher rates of 3‑P MACE versus those without CKD; in this subgroup Repatha reduced 3‑P MACE by 39%, 4‑P MACE by 23% and all‑cause mortality by 29%.
Long‑term FOURIER analysis
An external‑control comparison of FOURIER/OLE participants with UK health records over up to >8 years associated Repatha with a 29% lower rate of 3‑P MACE and a 25% lower risk of cardiovascular death, supporting durability of benefit beyond the randomized period.
Source: Amgen